- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Aetna Sees Promise in New Heart Disease Diagnostic
With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.
With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.
Members of Aetna and its Coventry subsidiary now have access to a gene expression blood test that helps diagnose obstructive coronary artery disease, a condition often investigated with stress testing, electrocardiograms, CT scans, dye-based angiography or catheterizations.
Under Aetna’s new clinical policy, a coronary artery disease (CAD) gene expression test sold by the company CardioDX will be covered as medically necessary for non-diabetic adult members experiencing chest pain or similar symptoms without a history of CAD.
Read the full story here: http://bit.ly/1r8gT8D
Source: Healthcare Payer News
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
